COMPANY PROFILE

OmniSeq

Explore full profile

Molecular diagnostic laboratory based in buffalo, new york

Buffalo, United StatesFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2017

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About OmniSeq

OmniSeq operates at the forefront of cancer diagnostics, specializing in immune and genomic profiling to guide therapeutic management for cancer patients with advanced solid tumors. The company serves oncologists and their patients, providing critical insights for immunotherapy and targeted therapy decisions. OmniSeq's business model revolves around its proprietary molecular sequencing assays, which analyze DNA and RNA to identify genetic alterations linked to drug responses. This enables personalized treatment plans based on curated evidence from pathologists. The company generates revenue by offering these advanced diagnostic tests to healthcare providers, ensuring timely and actionable results. OmniSeq's market includes hospitals, cancer treatment centers, and research institutions focused on precision medicine.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Buffalo, United States
Employees: 25
Open positions: None listed
Dealroom signal: 67.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCEquity / VC	Jun 2019	$1.6M	$6.3M	Undisclosed	—
SERIES B✓Equity / VC	Oct 2017	$10M	$40M	LabCorp	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

OmniSeq website traffic

Latest recorded traffic for OmniSeq is 4K monthly website visits, up 1112.1% over the last three months. OmniSeq's team grew 0% over the past year.

Latest monthly visits4K 3-month web change+1112.1% 1-year team growth0%

Monthly website visitsOct 2017–Nov 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RBRidge BiotechnologiesAI-enabled platform for precision enzyme and drug design	Palo Alto, United States	Operational	15	$63M	$152M
HTHalda TherapeuticsPrecision oncology therapies targeting cancer via RIPTAC™ chimera	New Haven, United States	Acquired
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
ATAbdera TherapeuticsUses antibody engineering to design and develop new precision radiotherapeutics for cancer	South San Francisco, United States	Operational
BTBright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases	Basel, Switzerland	Operational
NUNuvalentTargeted small-molecule cancer therapies for kinase-driven cancers	Cambridge, United States	Acquired
CTCertis TherapeuticsDeveloped minimally invasive therapy solutions based on real-time MRI guidance	Pessac, France	Operational